Apollomics Inc. Update on Agreement with LaunXP

Apollomics Inc. has provided an update on its agreement with LaunXP International Co., Ltd. regarding the development and commercialization of vebreltinib in Asia (excluding mainland China, Hong Kong, and Macau). In a previous filing on July 25, 2025, Apollomics disclosed that LaunXP had not fully satisfied its payment obligations under the agreement. The company had notified LaunXP of the breach and engaged in discussions to resolve the matter. In this update, Apollomics reports that it has recently received a payment of US$3,900,000 from LaunXP. The agreement remains in full force and effect, with both parties continuing to perform their respective obligations and maintain active discussions to advance the ongoing collaboration. This information is incorporated by reference into the company's registration statements under the Securities Act.